Laura Brege

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada.

COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction

Zvents, Inc. creates and operates local entertainment guides online. Its publications promote a range of local events and activities, including live music, performing arts, sporting events and community activities. The company was founded by Tyler Kovacs and Ethan Stock in 2005 and is headquartered in San Mateo, CA.

Flextronics Corp. provides fiberoptics and electronics manufacturing services. The company is located in Westford, MA.

Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA.

Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.

Portola Pharmaceuticals LLC engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Council on International Educational Exchange, Inc. provides educational services. The firm is a non-profit study abroad and intercultural exchange organization, transforms lives and builds bridges by promoting the exchange of ideas and experiences. It offers opportunities for cultural exchange, including work exchange programs, teach abroad programs, and a worldwide portfolio of study abroad and internship programs for college and high school students. The company was founded in 1947 and is headquartered in Portland, ME.

Pacira Pharmaceuticals, Inc. develops and manufactures injectable and sustained release therapeutic products. It focuses on clinical and commercial development activities by understanding the needs of the acute care market. The company was founded in March 2007 and is headquartered in San Diego, CA.

Part of T-Knife GmbH, T-Knife Therapeutics is a biopharmaceutical company based in San Francisco, CA. T-Knife Therapeutics, Inc. specializes in the development of novel therapeutics to fight cancer, with a focus on T cell receptor (TCR) engineered T cell therapies. T-Knife's unique approach is based on its proprietary MyT platform, which uses a next-generation T cell and epitope discovery engine to produce fully human, tumor-specific TCRs. The company's pipeline includes TCR-T product candidates targeting solid tumor targets with high unmet medical need. The CEO of the company is Thomas M. Soloway.

California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019.